Adjunctive glucocorticoid therapy in patients with septic shock.
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Whether hydrocortisone reduces mortality among patients with septic shock is unclear. METHODS: We randomly assigned patients with septic shock who were undergoing mechanical ventilation to receive hydrocortisone (at a dose of 200 mg per day) or placebo for 7 days or until death or discharge from the intensive care unit (ICU), whichever came first. The primary outcome was death from any cause at 90 days. RESULTS: From March 2013 through April 2017, a total of 3800 patients underwent randomization. Status with respect to the primary outcome was ascertained in 3658 patients (1832 of whom had been assigned to the hydrocortisone group and 1826 to the placebo group). At 90 days, 511 patients (27.9%) in the hydrocortisone group and 526 (28.8%) in the placebo group had died (odds ratio, 0.95; 95% confidence interval [CI], 0.82 to 1.10; P=0.50). The effect of the trial regimen was similar in six prespecified subgroups. Patients who had been assigned to receive hydrocortisone had faster resolution of shock than those assigned to the placebo group (median duration, 3 days [interquartile range, 2 to 5] vs. 4 days [interquartile range, 2 to 9]; hazard ratio, 1.32; 95% CI, 1.23 to 1.41; P<0.001). Patients in the hydrocortisone group had a shorter duration of the initial episode of mechanical ventilation than those in the placebo group (median, 6 days [interquartile range, 3 to 18] vs. 7 days [interquartile range, 3 to 24]; hazard ratio, 1.13; 95% CI, 1.05 to 1.22; P<0.001), but taking into account episodes of recurrence of ventilation, there were no significant differences in the number of days alive and free from mechanical ventilation. Fewer patients in the hydrocortisone group than in the placebo group received a blood transfusion (37.0% vs. 41.7%; odds ratio, 0.82; 95% CI, 0.72 to 0.94; P=0.004). There were no significant between-group differences with respect to mortality at 28 days, the rate of recurrence of shock, the number of days alive and out of the ICU, the number of days alive and out of the hospital, the recurrence of mechanical ventilation, the rate of renal-replacement therapy, and the incidence of new-onset bacteremia or fungemia. CONCLUSIONS: Among patients with septic shock undergoing mechanical ventilation, a continuous infusion of hydrocortisone did not result in lower 90-day mortality than placebo. (Funded by the National Health and Medical Research Council of Australia and others; ADRENAL ClinicalTrials.gov number, NCT01448109 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Since then, three large RCTs have been published [354, 478, 479].”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [479]
In the citing paper
“The optimal dose, timing of initiation, and duration of corticosteroids remain uncertain; recent RCTs used 200 mg per day of IV hydrocortisone in divided doses [354, 479].”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [479]
In the citing paper
“The three trials [354, 478, 479] also used different inclusion criteria: in ADRENAL [479] eligible patients were those on any dose of vasopressor or inotrope for ≥ 4 h to maintain a MAP > 60 mmHg, and present at the time of randomisation.”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [479]
In the citing paper
“In the ADRENAL [479] study, hydrocortisone was administered for a maximum of seven days or until ICU discharge or death; in APROCCHSS [478] hydrocortisone was administered for seven days; in VANISH [354] 200 mg of hydrocortisone was administered daily for 5 days and then tapered over further 6 days.”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [479]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The third international consensus definitions for sepsis and septic shock (Sepsis-3).
Singer, M., Deutschman, C. S., Seymour, C. W., Shankar-Hari, M., Annane, D., Bauer, M., Bellomo, R., Bernard, G. R., Chiche, J.-D., Coopersmith, C. M., et al. (2016) · JAMA · doi:10.1001/jama.2016.0287 · Cited by 28,250
Self-citationA Simple Sequentially Rejective Multiple Test Procedure
(1979) · Scandinavian Journal of Statistics · doi:10.2307/4615733 · Cited by 21,526
APACHE II: A severity of disease classification system
KNAUS, W. A., DRAPER, E. A., WAGNER, D. P., & ZIMMERMAN, J. E. (1985) · Critical Care Medicine · doi:10.1097/00003246-198510000-00009 · Cited by 13,664
Bone, R. C., Balk, R. A., Cerra, F. B., Dellinger, R. P., Fein, A. M., Knaus, W. A., Schein, R. M. H., & Sibbald, W. J. (1992) · Chest · doi:10.1378/chest.101.6.1644 · Cited by 13,198
Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock: 2016.
Rhodes, A., Evans, L. E., Alhazzani, W., Levy, M. M., Antonelli, M., Ferrer, R., Kumar, A., Sevransky, J. E., Sprung, C. L., Nunnally, M. E., et al. (2017) · Intensive Care Medicine · doi:10.1007/s00134-017-4683-6 · Cited by 6,621
Self-citationFleischmann, C., Scherag, A., Adhikari, N. K. J., Hartog, C. S., Tsaganos, T., Schlattmann, P., Angus, D. C., & Reinhart, K. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201504-0781oc · Cited by 3,548
Annane, D. (2002) · JAMA · doi:10.1001/jama.288.7.862 · Cited by 3,087
The Hypothalamic–Pituitary–Adrenal Axis and Immune-Mediated Inflammation
Chrousos, G. P. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505183322008 · Cited by 2,579
Hydrocortisone Therapy for Patients with Septic Shock
Sprung, C. L., Annane, D., Keh, D., Moreno, R., Singer, M., Freivogel, K., Weiss, Y. G., Benbenishty, J., Kalenka, A., Forst, H., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa071366 · Cited by 2,132
Incidence and trends of sepsis in US hospitals using clinical vs claims data, 2009-2014.
Rhee, C., Dantes, R., Epstein, L., Murphy, D. J., Seymour, C. W., Iwashyna, T. J., Kadri, S. S., Angus, D. C., Danner, R. L., Fiore, A. E., et al. (2017) · JAMA · doi:10.1001/jama.2017.13836 · Cited by 1,884
Cited by
Items 301–400 of 1,000
Mineralocorticoid Dysfunction during Critical Illness: A Review of the Evidence
Nethathe, G. D., Cohen, J., Lipman, J., Anderson, R., & Feldman, C. H. (2020) · Anesthesiology · doi:10.1097/aln.0000000000003365 · Cited by 22
Self-citationHydrocortisone with fludrocortisone for septic shock: a systematic review and meta‐analysis
Yamamoto, R., Nahara, I., Toyosaki, M., Fukuda, T., Masuda, Y., & Fujishima, S. (2020) · Acute Medicine & Surgery · doi:10.1002/ams2.563 · Cited by 29
Corticosteroid-Binding Globulin Deficiency Independently Predicts Mortality in Septic Shock
Meyer, E. J., Nenke, M. A., Davies, M. L., Chapman, M. J., Rankin, W. A., Rushworth, R. L., & Torpy, D. J. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac035 · Cited by 24
Sutrisno, W., & Dzhyvak, V. G. (2024) · Deka in Medicine · doi:10.69863/dim.v1i1.5 · Cited by 20
Honarmand, K., Um, K. J., Belley‐Côté, E. P., Alhazzani, W. A., Farley, C., Fernando, S. M., Fiest, K. M., Grey, D., Hajdini, E., Herridge, M. S., et al. (2019) · Canadian Journal of Anesthesia/Journal canadien d anesthésie · doi:10.1007/s12630-019-01546-x · Cited by 21
Duan, Y., Ou, X., Chen, Y., Liang, B., & Ou, X. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2020.602732 · Cited by 25
“Glucocorticoids was generally considered to be an important cause of aspergillus co-infection in patients with severe influenza, as glucocorticoids was frequently used in severe influenza patients with septic shock or acute respiratory distress syndrome (ARDS) (11, 12).”
BackgroundMehta, Y. B., Dixit, S., Zirpe, K. G., Sud, R., Gopal, P. B. N., Koul, P. A., Mishra, V. K., Ansari, A. S., & Chamle, V. S. (2021) · Cureus · doi:10.7759/cureus.18393 · Cited by 24
Systemic corticosteroids for management of COVID-19: Saving lives or causing harm?
FakhriRavari, A., Jin, S., Kachouei, F. H., Le, D., & Lopez, M. (2021) · International Journal of Immunopathology and Pharmacology · doi:10.1177/20587384211063976 · Cited by 21
“The 2018 ADRENAL trial was a randomized control trial to determine whether administration of hydrocortisone 200 mg IV continuously resulted in a lower 90-daymortality in comparison to a placebo.(38) Although nomortality benefits were seen (OR 0.”
BackgroundAmponsah, S. K., Tagoe, B., Adams, I., & Bugyei, K. A. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1063246 · Cited by 24
“Although there is no discernible reduction in mortality, steroids have shown good efficacy in stabilizing hemodynamics, reducing intensive care unit (ICU) stay and duration of mechanical breathing (Venkatesh et al., 2018).”
BackgroundCirculatory shock in adults in emergency department
Pannu, A. K. (2023) · Turkish Journal of Emergency Medicine · doi:10.4103/2452-2473.367400 · Cited by 21
Obling, L. E. R., Beske, R. P., Meyer, M., Grand, J., Wiberg, S. C., Mohr, T. T., Damm-Hejmdal, A., Forman, J. L., Frikke‐Schmidt, R., Folke, F., et al. (2024) · Critical Care · doi:10.1186/s13054-024-04808-3 · Cited by 20
“Glucocorticoids have previously been associated with faster shock resolution and reduced need for vasopres-sors [10, 11].”
BackgroundResultGlucocorticoid therapy for acute respiratory distress syndrome: Current concepts
Zhao, Y., Yao, Z., Xu, S., Yao, L., & Yu, Z. (2024) · Journal of Intensive Medicine · doi:10.1016/j.jointm.2024.02.002 · Cited by 24
Adaptive designs in clinical trials in critically ill patients: principles, advantages and pitfalls
van Werkhoven, C. H., Harbarth, S., & Bonten, M. J. M. (2018) · Intensive Care Medicine · doi:10.1007/s00134-018-5426-z · Cited by 20
Vassiliou, A. G., Stamogiannos, G., Jahaj, E., Botoula, E., Floros, G., Vassiliadi, D. A., Ilias, Ι., Tsagarakis, S., Tzanela, M., Orfanos, S. E., et al. (2019) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2019.110656 · Cited by 22
Fisse, A. L., May, C., Motte, J., Pedreiturria, X., Breuer, T. G. K., Schneider‐Gold, C., Marcus, K., Gold, R., Yoon, M., & Pitarokoili, K. (2020) · Neurocritical Care · doi:10.1007/s12028-020-01148-2 · Cited by 20
Ye, H., Li, P., Zhai, Q., Yang, S., Yang, S., Sun, Y., Wu, S., Huang, R., 陈齐兴, & Fang, X. (2021) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2021.111178 · Cited by 20
Cytokine storms, evolution and COVID-19
Alcock, J., & Masters, A. (2021) · Evolution Medicine and Public Health · doi:10.1093/emph/eoab005 · Cited by 22
“mixed results, but the largest multicenter randomized controlled trial showed no improvement in short- or long-term survival [31].”
Sobolewska, J., Działach, Ł., Kuca, P., & Witek, P. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1473151 · Cited by 23
Current standard of care for septic shock
Delaney, A. P., Borges-Sa, M., Chew, M. S., Waele, J. J. D., Dye, J., Khanna, A. K., Hamzaoui, O., Hammond, N. E., Glenn Hernández, P., Herridge, M. S., et al. (2025) · Intensive Care Medicine · doi:10.1007/s00134-025-08211-6 · Cited by 24
“Trials using intravenous hydrocortisone alone at a dose of 200mg/day have not demonstrated a reduction in mortality [56], but a combination of fludrocorti-sone plus hydrocortisone was shown to reduce mortality as compared to placebo [57].”
Self-citationWentowski, C. C., Mewada, N., & Nielsen, N. D. (2018) · Anaesthesia & intensive care medicine · doi:10.1016/j.mpaic.2018.11.009 · Cited by 29
He, J., Zhao, T., Liu, L., Liao, S., Yang, S., Lu, F., Hong, Y., Wei, N., Cheng, H., Zhang, W., et al. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108385 · Cited by 19
Glucocorticoid Therapy in Respiratory Illness: Bench to Bedside
Amratia, D., Viola, H., & Ioachimescu, O. C. (2022) · Journal of Investigative Medicine · doi:10.1136/jim-2021-002161 · Cited by 21
“153 210 At the same time, one should remember that CS use in the intensive care setting could be associated with critical illness polyneurop-athy, critical illness myopathy and/or delirium.”
Nanotechnology Applications in Sepsis: Essential Knowledge for Clinicians
Vasconcelos, I., & Santos, T. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15061682 · Cited by 21
Lyu, Q., Chen, Q., Zheng, R., Yu, J., & Gu, X. (2018) · Journal of Intensive Care Medicine · doi:10.1177/0885066618803062 · Cited by 20
“Fludrocortisone was administered in 2 trials(9,15) while the other 11 trials applied hydrocortisone only.(7,8,10,14,16,19-24) The taper off protocol was Figure 1.”
BackgroundResultNi, Y.-N., Liu, Y.-M., Wang, Y., Liang, B., & Liang, Z. (2018) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2018.11.040 · Cited by 20
“The 28-day mortality was recorded in 18 studies [9,10,13-19,21-28], mortality at longest follow up was reported in 19 studies [9,10,13-29], the occurrence of septic shock was reported in 2 studies [21,26], and the reoccurrence of septic shock was reported in 9 studies [9,10,1316,24,26,27].”
BackgroundInfluentialChen, L., Singh, S. P., Schuster, M., Grinenko, T., Bornstein, S. R., & Kanczkowski, W. (2019) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2019.04.009 · Cited by 19
Clinical Update in Pediatric Sepsis: Focus on Children With Pre-Existing Heart Disease
Weiss, S. L., Nicolson, S. C., & Naim, M. Y. (2019) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2019.10.029 · Cited by 37
Moskowitz, A. L., Andersen, L. W., Holmberg, M. J. J., Grossestreuer, A. V., Berg, K. M., & Granfeldt, A. (2020) · Critical Care · doi:10.1186/s13054-020-03113-z · Cited by 20
“An illustrative example is the APROCCHSS and ADRENAL trials, both investigating the effects of glucocorticoid therapy in patients with septic shock [17, 18].”
BackgroundMethodBosch, N. A., Teja, B. J., Wunsch, H., & Walkey, A. J. (2021) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202102-196oc · Cited by 19
Vasoplegia in Heart, Lung, or Liver Transplantation: A Narrative Review
Ortoleva, J. P., Dalia, A. A., Convissar, D. L., Pisano, D. V., Bittner, E. A., & Berra, L. M. (2025) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2025.01.012 · Cited by 18
Haemodynamic management of septic shock
Kotani, Y., Ryan, N., Udy, A. A., & Fujii, T. (2025) · Burns & Trauma · doi:10.1093/burnst/tkae081 · Cited by 22
The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2024
Shime, N., Nakada, T., Yatabe, T., Yamakawa, K., Aoki, Y., Inoue, S., Iba, T., Ogura, H., Kawai, Y., Kawaguchi, A., et al. (2025) · Acute Medicine & Surgery · doi:10.1002/ams2.70037 · Cited by 27
The Global Impact of Sepsis: Epidemiology, Recognition, Management, and Health System Challenges
Via, L. L., Ferlito, S., Modica, M. S. D., Marıno, A., Nunnari, G., Cacopardo, B. S., Lechien, J. R., Lentini, M., Lavalle, S., Botto, C. G., et al. (2026) · Epidemiologia · doi:10.3390/epidemiologia7010020 · Cited by 26
Wen, Y., Zhu, Y., Qimin, J., Guo, N., Cai, Y., & Shen, X. (2018) · Shock · doi:10.1097/shk.0000000000001202 · Cited by 18
“(11) Low risk Low risk Double Qing-quan et al.”
BackgroundWhy Understanding Sepsis Endotypes Is Important for Steroid Trials in Septic Shock
Antcliffe, D. B., & Gordon, A. C. (2019) · Critical Care Medicine · doi:10.1097/ccm.0000000000003833 · Cited by 18
Vasoplegia: Mechanism and Management Following Cardiopulmonary Bypass
Muhammad, R., Dharmadjati, B. B., Mulia, E. P. B., & Rachmi, D. A. (2022) · Eurasian Journal of Medicine · doi:10.5152/eurasianjmed.2022.20394 · Cited by 18
Discovery of fusidic acid derivatives as novel STING inhibitors for treatment of sepsis
Long, J., Ying, T., Zhang, L., Yu, T., Wu, J., Liu, Y., Li, X., You, G., Zhang, L., & Bi, Y. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114814 · Cited by 18
Performance of Pediatric Mortality Prediction Scores for PICU Mortality and 90-Day Mortality*
Jacobs, A., Flechet, M., Vanhorebeek, I., Verstraete, S., Ingels, C., Casaer, M. P., Soto‐Campos, G., Verbruggen, S. C. A. T., Joosten, K., Güiza, F., et al. (2018) · Pediatric Critical Care Medicine · doi:10.1097/pcc.0000000000001764 · Cited by 21
Less is more: catecholamine-sparing strategies in septic shock
Venkatesh, B., Khanna, A. K., & Cohen, J. (2019) · Intensive Care Medicine · doi:10.1007/s00134-019-05770-3 · Cited by 18
Self-citationAngiotensin II in Decompensated Cirrhosis Complicated by Septic Shock
Coleman, P. J., Nissen, A. P., Kim, D. E., Ainsworth, C., McCurdy, M. T., Mazzeffi, M. A., & Chow, J. H. (2019) · Seminars in Cardiothoracic and Vascular Anesthesia · doi:10.1177/1089253219877876 · Cited by 18
“This trial was unable to detect any mortality benefit, but like APROCCHSS, it was able to detect faster resolution of shock and shorter duration of mechanical ventilation with the use of corticosteroids.(40,41) Patients with critical illness are also deficient in thiamine, and its administration within 24 hours of adm…”
MethodResultRisk predictive role of hypernatremia for occurrence of sepsis-induced acute kidney injury
Zhi, D., Lin, J., Dong, L., Ji, X., Zhuang, H., Liu, Z., Liu, J., & Duan, M. (2021) · Annals of Palliative Medicine · doi:10.21037/apm-21-792 · Cited by 20
“However, the Adjunctive Corticosteroid Treatment in Critically Ill Patients with Septic Shock (ADRENAL) trial showed a significantly different result that the mortality was not decreased (27).”
BackgroundWu, C.-H., Guo, L., Hao, D., Wang, Q., Ye, X., Ito, M., Huang, B., Mineo, C., Shaul, P. W., & Li, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1110516 · Cited by 26
“TheADRENAL trail involving 3800 septic shock patients (without distinguishing the status of RAI) did not show survival benefits (13, 14).”
BackgroundVincent, J., Marini, J. J., & Pesenti, A. M. (2018) · Intensive Care Medicine · doi:10.1007/s00134-018-5220-y · Cited by 18
Vitamin C and thiamine for sepsis: time to go back to fundamental principles
Fujii, T., Fowler, R., & Vincent, J. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-06242-9 · Cited by 18
Schlapbach, L. J., GIBBONS, K. S., Ridolfi, R., Harley, A., Cree, M., Long, D. A., Buckley, D. H. F., Erickson, S. J., Festa, M., George, S., et al. (2021) · Frontiers in Pediatrics · doi:10.3389/fped.2021.663435 · Cited by 18
Self-citationAlkadri, J., Aucoin, S. D., McDonald, B. J., Grubic, N., & McIsaac, D. I. (2022) · British Journal of Anaesthesia · doi:10.1016/j.bja.2022.07.013 · Cited by 17
Shaker, E. H., Soliman, A. M., Bedewy, A. A. E., & Elrawas, M. M. (2025) · BMC Anesthesiology · doi:10.1186/s12871-024-02792-3 · Cited by 17
Adjunctive Therapies for Community-Acquired Pneumonia
Ceccato, A., Ferrer, M., Barbeta, E., & Torres, A. (2018) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2018.07.008 · Cited by 18
Hydrocortisone in Vasodilatory Shock
Venkatesh, B., & Cohen, J. (2019) · Critical Care Clinics · doi:10.1016/j.ccc.2018.11.005 · Cited by 20
Self-citationMohr, E. T. B., Nascimento, M. V. P. D. S., da Rosa, J. S., Vieira, G. N., Kretzer, I. F., Sandjo, L. P., & Dalmarco, E. M. (2019) · Mediators of Inflammation · doi:10.1155/2019/6474168 · Cited by 21
“However, the use of glucocorticoids as an adjuvant therapy to prevent the progression of ALI to circulatory and metabolic dysfunction is an approach used worldwide [20, 21].”
MethodMoskowitz, A. L., Yankama, T. T., Andersen, L. W., Huang, D. T., Donnino, M. W., & Grossestreuer, A. V. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-034406 · Cited by 17
Immune Response Resetting as a Novel Strategy to Overcome SARS-CoV-2–Induced Cytokine Storm
Nowill, A. E., & de Campos-Lima, P. O. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2000892 · Cited by 17
Tanaka, T., Mori, M., Sekino, M., Higashijima, U., Takaki, M., Yamashita, Y., Kakiuchi, S., Tashiro, M., Morimoto, K., Tasaki, O., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-93649-z · Cited by 18
Glucocorticoid and mineralocorticoid receptor expression in critical illness: A narrative review
Vassiliou, A. G., Athanasiou, N., Vassiliadi, D. A., Jahaj, E., Keskinidou, C., Kotanidou, Α., & Dimopoulou, I. (2021) · World Journal of Critical Care Medicine · doi:10.5492/wjccm.v10.i4.102 · Cited by 21
Téblick, A., Bruyn, L. D., Oudenhove, T. V., Perre, S. V., Pauwels, L., Derde, S., Langouche, L., & den Berghe, G. V. (2021) · Endocrinology · doi:10.1210/endocr/bqab222 · Cited by 21
Kamps, N. N., Banks, R., Reeder, R., Berg, R. A., Newth, C. J. L., Pollack, M. M., Meert, K. L., Carcillo, J. A., Mourani, P. M., Sorenson, S., et al. (2022) · Pediatric Critical Care Medicine · doi:10.1097/pcc.0000000000003009 · Cited by 18
Gangopadhyay, K. K., Mukherjee, J. J., Sinha, B., & Ghosal, S. (2023) · Journal of Radiology and Clinical Imaging · doi:10.26502/jrci.2809076 · Cited by 18
Cardiovascular Responses During Sepsis
Pecchiari, M., Pontikis, K., Alevrakis, E., Vasileiadis, I., Kompoti, M., & Koutsoukou, A. (2021) · Comprehensive physiology · doi:10.1002/cphy.c190044 · Cited by 19
Controversies in Sepsis Management—What is the Way Forward?
Lo, A. H., Kee, A. C. L., Li, A., & Rubulotta, F. M. (2020) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.202090 · Cited by 16
Watanabe, S., Liu, K., Morita, Y., Kanaya, T., Naito, Y., Suzuki, S., & Hasegawa, Y. (2022) · Progress in Rehabilitation Medicine · doi:10.2490/prm.20220013 · Cited by 20
Wang, W., Hu, Z., Mo, W., Ouyang, M., Lin, S., Li, X., Wang, C., Yu, F., Wang, Y., & Zhou, D. (2024) · Engineered Regeneration · doi:10.1016/j.engreg.2024.01.001 · Cited by 16
Cohen, J., Bellomo, R., Billot, L., Burrell, L. M., Evans, D. M., Finfer, S. R., Hammond, N. E., Li, Q., Liu, D. C., McArthur, C. J., et al. (2020) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202002-0281oc · Cited by 17
Self-citationSeptic Shock: A Genomewide Association Study and Polygenic Risk Score Analysis
D’Urso, S., Rajbhandari, D., Peach, E., de Guzman, E., Li, Q., Medland, S. E., Gordon, S. D., Martin, N. G., CHARGE Inflammation Working Group, Ligthart, S., et al. (2020) · Twin Research and Human Genetics · doi:10.1017/thg.2020.60 · Cited by 16
Self-citationSepsis in children: state-of-the-art treatment
Peshimam, N., & Nadel, S. (2021) · Therapeutic Advances in Infectious Disease · doi:10.1177/20499361211055332 · Cited by 28
Meyer, E. J., Nenke, M. A., Rankin, W. A., Lewis, J. G., Konings, E. E. M., Slager, M. A., Jansen, T. C., Bakker, J., Hofland, J., Feelders, R. A., et al. (2018) · Clinical Endocrinology · doi:10.1111/cen.13844 · Cited by 18
Catecholamines in sepsis: pharmacological insights and clinical applications—a narrative review
Belfiore, J., Taddei, R., & Biancofiore, G. (2025) · Journal of Anesthesia Analgesia and Critical Care · doi:10.1186/s44158-025-00241-2 · Cited by 24
Poole, A. P., Chaba, A., Bellomo, R., Bailey, M., Deane, A. M., Delaney, A. P., Eastwood, G. M., Haines, K. J., Hammond, N. E., Hensman, T., et al. (2025) · Intensive Care Medicine · doi:10.1007/s00134-025-08162-y · Cited by 16
“Sepsis and septic shock have been the focus of numerous pivotal clinical trials over the last two decades, with limited success [6–8].”
Self-citationThe endothelial-immunothrombotic storm in viral sepsis: lessons from COVID-19
Zhou, K., Chen, Y., Pang, J., Zhang, J., & Lu, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1681764 · Cited by 16
Differential benefits of steroid therapies in adults following major burn injury
Al‐Tarrah, K., Tan, P., Acharjee, A., Hazeldine, J., Torlińska, B., Wilson, Y. T., Torliński, T., Moiemen, N. S., & Lord, J. M. (2022) · Journal of Plastic Reconstructive & Aesthetic Surgery · doi:10.1016/j.bjps.2022.04.007 · Cited by 15
New, Useful Criteria for Assessing the Evidence of Infection in Sepsis Research
Mellhammar, L., Elén, S., Ehrhard, S., Bouma, H. R., Ninck, L., Muntjewerff, E., Wünsch, D., Bloos, F., Malmström, E., & Linder, A. (2022) · Critical Care Explorations · doi:10.1097/cce.0000000000000697 · Cited by 21
Hydrocortisone and Risk Factors for Kidney Replacement Therapy in Septic Shock
Donaldson, L., Devaux, A., White, K. C., Rajbhandari, D., Cohen, J., Bellomo, R., Myburgh, J., Hammond, N. E., & Venkatesh, B. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.12279 · Cited by 16
Self-citationMarino, L. O., & de Souza, H. P. (2020) · European Journal of Emergency Medicine · doi:10.1097/mej.0000000000000693 · Cited by 17
Perceptions regarding vasopressin use and practices in septic shock, and cost containment strategies
Hammond, D. A., Rech, M. A., Daley, M. J., Devlin, J. W., Hodge, E. K., Kooda, K. J., Lat, I., Personett, H. A., Roberts, R. J., Sacha, G. L., et al. (2019) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.1079 · Cited by 15
The controversial role of corticosteroids in septic shock
Pourmand, A., Whiteside, T., Yamane, D. P., Rashed, A. L., & Mazer-Amirshahi, M. E. (2019) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2019.04.045 · Cited by 16
“did not find a difference in mortality but did see some positive hemodynamic effects from the hydrocortisone [15].”
BackgroundAngiotensin II Brings More Questions Than Answers.
Farina, N., Bixby, A. L., & Alaniz, C. (2018) · Europe PMC (PubMed Central) · Cited by 15
Current Controversies in Sepsis Management
Moss, S. R., & Prescott, H. C. (2019) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0039-1696981 · Cited by 15
The challenge of recognising sepsis: Future nanotechnology solutions
Claxton, A., Papafilippou, L., Hadjidemetriou, M., Kostarelos, K., & Dark, P. M. (2019) · Journal of the Intensive Care Society · doi:10.1177/1751143719896554 · Cited by 16
Glucocorticoids with or without Fludrocortisone in Septic Shock
Venkatesh, B., Finfer, S. R., & Myburgh, J. (2018) · New England Journal of Medicine · doi:10.1056/nejmc1804993 · Cited by 16
Self-citationHormonal Therapy in Organ Donors
Opdam, H. I. (2019) · Critical Care Clinics · doi:10.1016/j.ccc.2018.11.013 · Cited by 15
Glucocorticoid-Induced Leucine Zipper: A Promising Marker for Monitoring and Treating Sepsis
He, Y., Xu, J., Sun, M., Fang, X., Peng, Z.-K., Pan, S., Zhou, T., Wang, Y., & Shang, Y. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.606649 · Cited by 16
“However, the ADRENAL trial, which included 3800 patients, showed that septic patients who were treated with low-dose hydrocortisone did not exhibit reductions in 90-day mortality compared with the patients in the placebo group (4).”
BackgroundThe Eight Unanswered and Answered Questions about the Use of Vasopressors in Septic Shock
Hamzaoui, O., Goury, A., & Teboul, J. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12144589 · Cited by 17
Girardis, M., Coloretti, I., Antonelli, M. M., Berlot, G., Busani, S., Cortegiani, A., PASCALE, G. D., Rosa, F. G. D., Rosa, S. D., Donadello, K., et al. (2024) · Journal of Anesthesia Analgesia and Critical Care · doi:10.1186/s44158-024-00165-3 · Cited by 15
Wayland, J., Teixeira, J. P., & Nielsen, N. D. (2024) · Anaesthesia & intensive care medicine · doi:10.1016/j.mpaic.2024.06.010 · Cited by 23
Venkatesh, B., & Cohen, J. (2019) · Critical Care Medicine · doi:10.1097/ccm.0000000000003834 · Cited by 15
Self-citationEffect of hydrocortisone on the 28-day mortality of patients with septic acute kidney injury
Pan, Y., Yang, C., Wu, X., Cai, Q., & Xin, W. (2019) · Renal Failure · doi:10.1080/0886022x.2019.1658605 · Cited by 15
“(ADRENAL [7] and APROCCHSS [8]) reported in 2018”
BackgroundUpdates in Sepsis Resuscitation
Ellender, T. J., & Benzoni, N. S. (2020) · Emergency Medicine Clinics of North America · doi:10.1016/j.emc.2020.06.006 · Cited by 14
Park, Y. J., Lee, M. J., Bae, J., Lee, J. H., Lee, H. A. R., Mun, S., Kim, Y.-S., Yune, C. J., Chung, T. N., & Kim, K. (2022) · Life · doi:10.3390/life12030421 · Cited by 15
“In the early 2000s, low doses of steroids were used in clinical trials, and some reported beneficial effects [1,7,8,12,19].”
BackgroundApplying Lessons Learned From COVID-19 Therapeutic Trials to Improve Future ALI/ARDS Trials
Wu, Q., Pennini, M. E., Bergmann, J. N., Kozak, M., Herring, K. D., Sciarretta, K. L., & Armstrong, K. L. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac381 · Cited by 15
Berghe, T. V., & Hoste, E. A. J. (2018) · Cell Death and Differentiation · doi:10.1038/s41418-018-0196-2 · Cited by 20
“other could not demonstrate a beneficial effect [32, 33].”
BackgroundPrognostic utility of procalcitonin and lactate clearance for in-hospital mortality in sepsis
Diab, R., Chebl, R. B., Barmo, N., Siblini, R., Makki, M. H., Tamim, H., & Dagher, G. A. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1679297 · Cited by 14
Basic mechanisms in cardiogenic shock: part 2 – biomarkers and treatment options
Krychtiuk, K. A., Vrints, C. J., Wojta, J., Huber, K., & Speidl, W. S. (2022) · European Heart Journal Acute Cardiovascular Care · doi:10.1093/ehjacc/zuac022 · Cited by 13
Marik, P. E. (2018) · Surgical Infections · doi:10.1089/sur.2018.111 · Cited by 14
“In the three recent large randomized controlled trials, low-dose short-duration treatment with glucocorticoids was not associated with an increased risk of secondary infections [124–126].”
Zhou, X., Hu, C., Yao, L., Fan, Z., Sun, L., Wang, Y., & Xu, Z. (2018) · Journal of Critical Care · doi:10.1016/j.jcrc.2018.09.013 · Cited by 13
Jabaley, C. S., Groff, R. F., Barnes, T. J., Caridi-Scheible, M. E., Blum, J. M., & O’Reilly-Shah, V. N. (2019) · PLoS ONE · doi:10.1371/journal.pone.0221596 · Cited by 13
“12 10/7/2016 23,256 21 Coverage of a US Pediatric sepsis death linked to nutritional deficiency 13 12/3/2016 23,023 22 Coverage of childhood neglect and attempted murder (Tiffany Alberts) Death of a veteran in a VA facility from sepsis (Owen Reese Peterson) 14 3/10/2017 30,768 10 National Institute for Health and Care…”
Smarter Use of Corticosteroids in Treating Patients with Septic Shock
Prescott, H. C., & Sussman, J. B. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.29323 · Cited by 13
Inflammation, immunity and allergy
Stewart, D., & Nichol, A. (2018) · Anaesthesia & intensive care medicine · doi:10.1016/j.mpaic.2018.08.011 · Cited by 16
CIRMI—a new term for a concept worthy of further exploration: a narrative review
Nethathe, G. D., Lipman, J., Anderson, R., & Feldman, C. H. (2022) · Annals of Translational Medicine · doi:10.21037/atm-21-5572 · Cited by 15
“Evidence of benefit was demonstrated with regard to time to shock resolution, duration of mechanical ventilation, length of ICU stay and reduced frequency of blood transfusions (77).”
BackgroundInfluentialAbril, M. K., Khanna, A. K., Kroll, S., McNamara, C., Handisides, D. R., & Busse, L. W. (2018) · Journal of Critical Care · doi:10.1016/j.jcrc.2018.12.007 · Cited by 13
“The Adjunctive Corticosteroid Treatment in Critically Ill Patients with Septic Shock (ADRENAL) trial investigators noted a faster resolution of shock with a continuous infusion of hydrocortisone but no overall mortality benefit [22].”
BackgroundNandish, H. K., Arun, C. S., Nair, H. R., Rajesh, G., Kumar, H., & Venu, R. P. (2019) · The Journal of the Royal College of Physicians of Edinburgh · doi:10.4997/jrcpe.2019.405 · Cited by 13
Late Vasopressor Administration in Patients in the ICU
Viglianti, E. M., Bagshaw, S. M., Bellomo, R., McPeake, J. M., Molling, D. J., Wang, X. Q., Seelye, S. M., & Iwashyna, T. J. (2020) · CHEST Journal · doi:10.1016/j.chest.2020.02.071 · Cited by 13
Self-citation
Metadata
- Authors
- Venkatesh, B., Finfer, S., Cohen, J., Rajbhandari, D., Arabi, Y., Bellomo, R., Billot, L., Correa, M., Glass, P., Harward, M., Joyce, C., Li, Q., McArthur, C., Perner, A., Rhodes, A., Thompson, K., Webb, S., & Myburgh, J.
- Affiliations
- The University of Sydney (AU)
- From the George Institute for Global Health, University of New South Wales (B.V., S.F., D.R., L.B., M.C., P.G., M.H., Q.L., K.T., J.M.), St. George Clinical School, St. George Hospital (J.M.), Sydney Medical School, University of Sydney (B.V., S.F., J.M.), and Royal North Shore Hospital (S.F.), Sydney, the Princess Alexandra Hospital (B.V., C.J.) and Royal Brisbane and Women’s Hospital (J.C.), University of Queensland, and the Wesley Hospital (B.V., J.C.), Brisbane, Austin Hospital (R.B.), the...
- University of Copenhagen (DK)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-03
- Volume
- 378
- Issue
- 9
- Pages
- 797-808
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2784412824
- Cited by
- 1,037
- References
- 40
- Citations by year
- 2026: 111 · 2025: 122 · 2024: 90 · 2023: 106 · 2022: 110 · 2021: 121 · 2020: 149 · 2019: 135 · 2018: 91
- FWCI
- 96.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Monash University Research Portal (Monash University) (publishedVersion, other-oa)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- St George's Online Research Archive (St George's University of London) (acceptedVersion)
- UNSWorks (University of New South Wales, Sydney, Australia) (submittedVersion, cc-by-nc-nd)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- Research Repository (Kingston University London) (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- Funders
- National Health and Medical Research Council (1004108, 1124926)
- Health Research Council of New Zealand (12/206)
- National Institute of Health Research, United Kingdom
- Topics
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Keywords
- septic shock, cortisol, mortality, mechanical ventilation, shock resolution, blood transfusion, intensive care unit, sepsis treatment, subgroup analysis, mechanical ventilation duration, vasopressor requirement, glycemic control
- MeSH terms
- Aged, Anti-Inflammatory Agents, Double-Blind Method, Female, Humans, Hydrocortisone, Infusions, Intravenous, Male, Middle Aged, Recurrence, Respiration, Artificial, Shock, Septic, Survival Rate, Fungemia, Bacteremia, Treatment Outcome, Chemotherapy, Adjuvant, Renal Replacement Therapy, APACHE
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.